All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the EHA 2022 Congress, the GvHD Hub was pleased to speak to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, How do you optimize donor selection for allogeneic transplant? Comparing MSD, UD, and haploidentical donors.
How to optimize donor selection for allogeneic transplant?
Nagler begins by comparing leukemia-free and relapse-free survival with different donor types, including sibling, unrelated, mismatched, and haploidentical donors. Nagler goes on to talk about incidence of chronic GvHD (cGvHD) in transplant, and factors to consider when selecting a donor. Finally, Nagler discusses how to prevent GvHD and infections.
MRD-negativity after tandem autologous-allogeneic HSCT with bortezomib maintenance
During the 17th International Myeloma Workshop (IMW), in Boston, MA, US, a ‘Myeloma Transplant and Maintenance Strategies’ session was held on Saturday 14th September...
Subscribe to get the best content related to GvHD delivered to your inbox